Clearside Biomedical announced that several presentations were delivered at two prestigious medical conferences in February: the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. "The promising durability data from our OASIS clinical trial continues to garner significant attention as a potential treatment option for patients with wet AMD," said, George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer. "Our trial demonstrated that 67% of extension study participants went at least 6 months without needing additional treatment. Furthermore, detailed safety and tolerability data from OASIS reinforced the excellent safety profile for CLS-AX at all doses and timepoints for those patients with previously persistent, active disease. We were also pleased to see the promising data results from our partners utilizing our proprietary SCS Microinjector to administer gene therapy and oncology agents to treat wet AMD, diabetic retinopathy, and choroidal melanoma."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CLSD:
- Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
- Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
- Clearside Biomedical announces leadership update
- Clearside Biomedical Announces Leadership Team Update
- 3 Stocks to Buy Today, 2/3/2023, According to Top Analysts
